Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (RMD) is a health technology company focused on sleep, breathing, and care delivered in the home, and its news flow reflects that focus. Company announcements regularly describe how ResMed creates life-changing health technologies, combining AI-powered digital health solutions, cloud-connected devices, and intelligent software to support sleep and breathing therapy for people in more than 140 countries.
Investors following RMD news can expect updates on financial performance and capital returns, including quarterly earnings releases, dividend declarations, and details of investor webcasts. ResMed frequently issues press releases about its results of operations, margins, cash flow, and related board decisions such as quarterly cash dividends, as documented in its Form 8-K filings and Globe Newswire announcements.
ResMed’s news also highlights product and technology developments. Recent communications include FDA clearance for Smart Comfort, an AI-enabled digital medical device that recommends personalized comfort settings for CPAP therapy, and design awards for the AirTouch N30i nasal cradle mask. These stories often emphasize the use of real-world sleep data, machine learning, and human-centered design to improve comfort and adherence for people with obstructive sleep apnea.
Another recurring theme in ResMed’s news is research and clinical insights. The company has announced landmark studies in The Lancet Respiratory Medicine projecting future obstructive sleep apnea prevalence, as well as meta-analyses on CPAP therapy and mortality. It has also launched initiatives like Sleep Institute to publish evidence-based insights that inform care models and policy discussions around sleep health.
Corporate governance and investor-relations events appear frequently in RMD news as well, including participation in major healthcare conferences, updates on board composition, and details of annual meetings. For readers and investors, the RMD news page offers a centralized view of ResMed’s earnings, product clearances, research publications, and strategic initiatives related to sleep and breathing health.
ResMed (NYSE: RMD) has announced that Rob Douglas, president and COO, and Brett Sandercock, CFO, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2021, at 4:15 p.m. EDT. The event will be accessible via a video webcast. A replay will be available one hour post-event until June 21, 2021. ResMed focuses on innovative solutions to treat chronic diseases, providing digital health technologies and cloud-connected medical devices that enhance the quality of life for patients globally.
Summary not available.
MatrixCare announced that its Home Health and Hospice EHR solution has been awarded Best in KLAS for Home Health EHR (Large) for the second consecutive year. The solution achieved a Home Health score of 88.3, up from 87.1 last year, leading competitors by 2 points. In the Hospice category, MatrixCare leads by 13.2 points, to be recognized in next year's awards. The company focuses on innovation and customer support, especially during the pandemic, and will be acknowledged in a virtual awards ceremony on February 23.
ResMed reported a strong performance for the second quarter of 2021, with a 9% increase in revenue to $800.0 million. Net operating profit rose 12%, and GAAP diluted EPS grew to $1.23. These results were supported by growth in core markets like sleep apnea and COPD despite a 20 basis point contraction in gross margin due to restructuring expenses. Notably, non-GAAP EPS improved by 17%. The company also declared a quarterly cash dividend of $0.39 per share, demonstrating financial strength as it aims to enhance digital health solutions.
ResMed (NYSE: RMD, ASX: RMD) will release its financial and operational results for Q2 of fiscal 2021 on January 28, 2021, post-market close. A webcast is scheduled to follow, where management will discuss results and potentially other forward-looking information.
The earnings webcast will take place at 1:30 p.m. PST / 4:30 p.m. EST, with international times provided for London and Sydney. A replay will be available on ResMed’s website within two hours of the event and will also feature a phone replay option available until February 11.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at approximately 4:30 PM EST via webcast. The conference will provide insights into ResMed's innovative digital health technologies and cloud-connected medical devices, aimed at treating chronic diseases like sleep apnea and COPD. The audio-only webcast replay will be available about an hour after the presentation and remain accessible for 30 days.
ResMed has launched a new sleep education campaign, #WakeUpToGoodSleep, aimed at raising awareness of sleep disorders in India, where over one million people suffer from sleep apnea. The campaign emphasizes the critical impact of sleep quality on overall well-being, with untreated sleep disorders linked to health issues like diabetes and heart attacks. It also features a sleep coach assistant service to guide patients through sleep apnea detection and treatment options. Since May 2020, ResMed has trained over 700 doctors in sleep health education to enhance public awareness.
ResMed (NYSE: RMD) has announced that CEO Mick Farrell will participate in a virtual fireside chat at the Credit Suisse 29th Annual Global Healthcare Conference on November 10, 2020, at 5:00 p.m. EST. This event will be available via video webcast. More details and access to the live webcast can be found at investor.resmed.com. A replay will be accessible about an hour after the live event, remaining available until November 10, 2021.
ResMed (NYSE: RMD) plans to report its financial and operational results for Q1 FY 2021 on October 29, 2020, after market close. A management webcast will follow to discuss these results and additional forward-looking information. The earnings call is scheduled for 1:30 p.m. PDT / 4:30 p.m. EDT and will be accessible through ResMed's investor relations website.
The earnings call replay will be available for two weeks following the event. ResMed specializes in innovative health solutions for chronic diseases, enhancing care quality while reducing healthcare costs globally.
VIDA Diagnostics has appointed Karen Drexler to its board of directors, enhancing its leadership in digital health technology amid the ongoing COVID-19 pandemic. Drexler, an experienced entrepreneur with a background in digital health and established accolades, aims to support VIDA's mission to modernize lung and respiratory care. Her appointment is expected to bolster market expansion and innovation in AI-powered lung intelligence solutions, aligning with the heightened focus on lung health and the rising demand for advanced medical technologies.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
